Like a delivery driver navigating crowded city streets, a gene-therapy-toting lipid nanoparticle faces a gauntlet of potential detours on its journey toward a cell's nucleus. First, there's entering ...

The CRISPR therapy, SNIPR001, was administered following a single-patient emergency investigational new drug application.

Cambridge human cell programming company, has launched the ioScreen platform, a new CRISPR screening service designed to ...

For patients with blood cancers like leukemia and lymphoma, the immunotherapy known as CAR-T cell therapy can be lifesaving. Doctors remove a patient's immune cells, called T cells, engineer them in ...

The next six months may be decisive for the biotech.

The CEO spoke with BioPharma Dive about convincing investors to buy into the first gene editing IPO in more than two years.

Startups and Big Ag are using Crispr gene editing to create crops that taste better and grow on a hotter planet. But will they find a market?

CRISPR Therapeutics (CRSP) remains a Strong Buy, supported by robust CASGEVY sales growth and pipeline expansion.

Banas is associate director of research at the Gene Editing Institute at ChristianaCare, where Kmiec is founder and executive director. The medical promise of CRISPR gene editing can be seen most ...

Now, there is renewed hope that allergies won't get in the way of pet ownership.

Bacteria-killing phage viruses souped up with DNA-destroying CRISPR appear to have helped clear up a very serious infection caused by antibiotic-resistant E. coli ...

Could gene editing change dog allergies?